Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 10, 2019; 92 (15 Supplement) May 5, 2019

Phase 1 Study of Intrathecal Administration of AVXS-101 Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 2 (SMA2) (STRONG) (P1.6-059)

Richard S. Finkel, John W. Day, Basil T. Darras, Nancy L. Kuntz, Anne M. Connolly, Thomas Crawford, Russell J. Butterfield, Perry B. Shieh, Gihan Tennekoon, Susan T. Iannaccone, Matthew Meriggioli, Sidney A. Spector, Francis G. Ogrinc, James L’Italien, Courtney Wells, Brian Kaspar, Douglas M. Sproule, Douglas E. Feltner, Jerry R. Mendell
First published April 16, 2019,
Richard S. Finkel
1Nemours Children’s Hospital Orlando FL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John W. Day
2Stanford University Medical Center Palo Alto CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Basil T. Darras
3Boston Children’s Hospital Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy L. Kuntz
4Ann & Robert H Lurie Children’s Hospital of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne M. Connolly
5Washington University School of Medicine Saint Louis MO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Crawford
6Johns Hopkins Medicine Baltimore MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Russell J. Butterfield
7University of Utah Health Salt Lake City UT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Perry B. Shieh
8David Geffen School of Medicine at UCLA Los Angeles CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gihan Tennekoon
9Children’s Hospital of Philadelphia Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan T. Iannaccone
10University of Texas Southwestern Medical Center Dallas TX United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Meriggioli
11AveXis, Inc. Bannockburn IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sidney A. Spector
11AveXis, Inc. Bannockburn IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francis G. Ogrinc
11AveXis, Inc. Bannockburn IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James L’Italien
11AveXis, Inc. Bannockburn IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Courtney Wells
11AveXis, Inc. Bannockburn IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Kaspar
11AveXis, Inc. Bannockburn IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas M. Sproule
11AveXis, Inc. Bannockburn IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas E. Feltner
11AveXis, Inc. Bannockburn IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerry R. Mendell
12Nationwide Children’s Hospital Columbus OH United States
13Ohio State University Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Phase 1 Study of Intrathecal Administration of AVXS-101 Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 2 (SMA2) (STRONG) (P1.6-059)
Richard S. Finkel, John W. Day, Basil T. Darras, Nancy L. Kuntz, Anne M. Connolly, Thomas Crawford, Russell J. Butterfield, Perry B. Shieh, Gihan Tennekoon, Susan T. Iannaccone, Matthew Meriggioli, Sidney A. Spector, Francis G. Ogrinc, James L’Italien, Courtney Wells, Brian Kaspar, Douglas M. Sproule, Douglas E. Feltner, Jerry R. Mendell
Neurology Apr 2019, 92 (15 Supplement) P1.6-059;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To describe STRONG, a multicenter, open-label, phase 1 study (NCT03381729) of the safety, tolerability, optimal dose, and efficacy of onasemnogene abeparvovec (AVXS-101) in patients with SMA2.

Background: SMA is a rapidly progressing neurodegenerative disease causing loss of motor and respiratory function. The genetic root cause is bi-allelic deletion/mutation of the survival motor neuron 1 gene (SMN1). Disease severity is modified by SMN2 copy number. AVXS-101 comprises an adeno-associated virus serotype 9-encapsulated transcript of human SMN that crosses the blood-brain barrier. In a phase 1 study (NCT02122952) in patients with SMA1, intravenous AVXS-101 demonstrated unprecedented improvements in survival, motor function, and motor milestone achievement

Design/Methods: In STRONG, SMA2 patients (bi-allelic SMN1 mutations/deletions, 3 copies of SMN2) who could sit but not stand or walk independently were enrolled in 2 cohorts by age (cohort 1: ≥6 to <24 months; cohort 2: ≥24 to <60 months), received one-time intrathecal AVXS-101 at the highest acceptably safe dose, and were followed for 12 months. Three patients in cohort 1 received dose A. Based on demonstrated acceptable safety, three additional patients in cohort 2 received dose B. Given ongoing demonstration of acceptable safety, 13 additional patients in cohort 1 and 9 in cohort 2 were treated with dose B. Primary endpoints were safety/tolerability, optimal dose, ability to stand unsupported ≥3 sec (cohort 1), and Hammersmith Functional Motor Scale-Expanded score (cohort 2).

Results: As of October 12, 2018, 28 patients have been enrolled at 11 sites. Enrollment is complete. To date, no safety or tolerability concerns have been identified. A study update will be provided.

Conclusions: Results from STRONG show intrathecal delivery of AVXS-101 in infants is feasible and well tolerated, with no safety concerns to date, and may support AVXS-101 as a promising treatment option for patients with SMA2.

Disclosure: Dr. Finkel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ionis Pharmaceuticals, Inc. and Biogen, AveXis, Novartis, and Roche. Dr. Finkel has received royalty, license fees, or contractual rights payments from Licensing fees from Children’s Hospital of Philadelphia for development of the CHOP-INTEND motor scale. Dr. Finkel has received research support from Ionis Pharmaceuticals, Inc. and Biogen, grants from AveXis and Cytokinetics. Dr. Day has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AMO, Audentes, AveXis, Biogen, Cytokinetics, Santhera, and Sarepta. Dr. Day has received research support from AveXis, Biogen, Cytokinetics, Genzyme, Ionis, Roche, Santhera, and Sarepta. Dr. Darras has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Biogen, Bristol-Myers Squibb, Cytokinetics, Marathon, PTC Therapeutics, Roche, Santhera, and Sarepta. Dr. Darras has received research support from the National Institutes of Health/National Institute of Neurological Disorders and Stroke, the Slaney Family Fund for SMA, Working on Walking Fund, the SMA Foundation, CureSMA, Ionis Pharmaceuticals, Inc., Biogen, AveXis, Cytokinetics, Fibrogen, PTC Therapeutics, Roche, Santhera, Sarepta, and Summit. Dr. Kuntz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Audentes, AveXis, Catalyst, Cytokinetics, Marathon, PTC Therapeutics, and Sarepta Therapeutics. Dr. Kuntz has received research support from AveXis, Audentes, Biogen, Pfizer, Roche and Sarepta Therapeutics. Dr. Connolly has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Avexis, Sarepta, Astelles, Marathon, Accelleron, Roche, (advisory boards) and Catabasis (DMSB). Dr. Connolly has received research support from Clinical trial site PI for Avexis, Sarepta, Biogen, Cytokinetics, NS Pharma, Pfizer, Roche, Italfarmaco, Fibrogen, and Capricor. Dr. Crawford has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Biogen, Catalyst, Cure SMA, Cytokinetics, Marathon, Muscular Dystrophy Association, Novartis, Roche, Sarepta, Scholar Rock, and the Spinal Muscular Atrophy Foundation. Dr. Butterfield has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sarepta Therapeutics and Biogen. Dr. Butterfield has received research support from PTC Therapeutics, Sarepta Therapeutics, Pfizer, and, Biogen. Dr. Shieh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, AveXis, Inc., Biogen, Grifols, PTC Therapeutics and Sarepta. Dr. Shieh has received research support from AveXis, Inc., Audentes, Biogen, Bristol-Myers Squibb, Cytokinetics, Catalyst, Fibrogen, Ionis Pharmaceuticals, Inc., Marathon, Pfizer, PTC Therapeutics, Sarepta, Santhera, Summit, Sanofi/Genzyme and Ultragenyx. Dr. Tennekoon has received research support from Catabasis Pharmaceuticals. Dr. Iannaccone has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Avexis, Biogen, Sarepta, Capricor. Dr. Iannaccone has received research support from AveXis, Biogen, Sarepta, Capricor, Mallinckrodt, Fibrogen, Regeneron, PTC Therapeutics. Dr. Meriggioli has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Inc. Dr. Spector has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Inc. Dr. Ogrinc has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, a Novartis company. Dr. L’Italien has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Inc.. Dr. Wells has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, a Novartis company. Dr. Kaspar has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, a Novartis company. Dr. Sproule has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities as an employee of AveXis, a Novartis company. Dr. Sproule has received compensation for serving on the Board of Directors of AveXis, a Novartis company. Dr. Feltner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acadia, Embera Neurtherapeutics, AveXis, Inc. Dr. Feltner has received compensation for serving on the Board of Directors of Embera Neurotherapeutics. Dr. Feltner holds stock and/or stock options in AveXis, Inc. Dr. Mendell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Inc.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (4)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise